Impact of body weight on mycophenolic acid population pharmacokinetics in paediatric lupus nephritis: a pharmacogenomic integration study

Body weight emerges as the primary covariate over pharmacogenetic variants in PPK modelling of MPA in paediatric LN. We suggest that an individualised initial dose and adjustment based on body weight can be given in the paediatric population.